Epidermodysplasia Verruciformis: Inborn Errors of Immunity to Human Beta-Papillomaviruses

Epidermodysplasia verruciformis (EV) is an autosomal recessive skin disorder with a phenotype conditional on human beta-papillomavirus (beta-HPV) infection. Such infections are common and asymptomatic in the general population, but in individuals with EV, they lead to the development of plane wart-like and red or brownish papules or pityriasis versicolor-like skin lesions, from childhood onwards. Most patients develop non-melanoma skin cancer (NMSC), mostly on areas of UV-exposed skin, from the twenties or thirties onwards. At least half of the cases of typical EV are caused by biallelic loss-of-function mutations of TMC6/EVER1 or TMC8/EVER2. The cellular and molecular basis of disease in TMC/EVER-deficient patients is unknown, but a defect of keratinocyte-intrinsic immunity to beta-HPV is suspected. Indeed, these patients are not susceptible to other infectious diseases and have apparently normal leukocyte development. In contrast, patients with an atypical form of EV due to inborn errors of T-cell immunity invariably develop clinical symptoms of EV in the context of other infectious diseases. The features of the typical and atypical forms of EV thus suggest that the control of beta-HPV infections requires both EVER1/EVER2-dependent keratinocyte-intrinsic immunity and T cell-dependent adaptive immunity.

[1]  X. Mo,et al.  A novel homozygous DOCK8 mutation associated with unusual coexistence of gross molluscum contagiosum and epidermodysplasia verruciformis in a DOCK8 deficiency patient , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[2]  P. Itin,et al.  Novel TMC8 splice site mutation in epidermodysplasia verruciformis and review of HPV infections in patients with the disease , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[3]  R. Hoyos-Bachiloglu,et al.  Combined immunodeficiency with EBV positive B cell lymphoma and epidermodysplasia verruciformis due to a novel homozygous mutation in RASGRP1. , 2017, Clinical immunology.

[4]  B. Amin,et al.  Acquired Epidermodysplasia Verruciformis and Its Relationship to Immunosuppressive Therapy: Report of a Case and Review of the Literature. , 2017, Journal of drugs in dermatology : JDD.

[5]  C. Ma,et al.  Identification of LCK mutation in a family with atypical epidermodysplasia verruciformis with T‐cell defects and virus‐induced squamous cell carcinoma , 2016, The British journal of dermatology.

[6]  H. Shimizu,et al.  Genetic analysis of a novel splice‐site mutation in TMC8 reveals the in vivo importance of the transmembrane channel‐like domain of TMC8 , 2016, The British journal of dermatology.

[7]  J. Casanova Severe infectious diseases of childhood as monogenic inborn errors of immunity , 2015, Proceedings of the National Academy of Sciences.

[8]  P. Howley,et al.  Beta genus papillomaviruses and skin cancer. , 2015, Virology.

[9]  S. Tyring,et al.  Deleterious Effect of Radiation Therapy on Epidermodysplasia Verruciformis Patients , 2015, Journal of cutaneous medicine and surgery.

[10]  T. Brümmendorf,et al.  Early-onset Evans syndrome, immunodeficiency, and premature immunosenescence associated with tripeptidyl-peptidase II deficiency. , 2015, Blood.

[11]  J. Bouwes Bavinck,et al.  Characterization of skin lesions induced by skin‐tropic α‐ and β‐papillomaviruses in a patient with epidermodysplasia verruciformis , 2014, The British journal of dermatology.

[12]  J. Lupski,et al.  Compound Heterozygous CORO1A Mutations in Siblings with a Mucocutaneous-Immunodeficiency Syndrome of Epidermodysplasia Verruciformis-HPV, Molluscum Contagiosum and Granulomatous Tuberculoid Leprosy , 2014, Journal of Clinical Immunology.

[13]  R. Badolato,et al.  α- and β-papillomavirus infection in a young patient with an unclassified primary T-cell immunodeficiency and multiple mucosal and cutaneous lesions. , 2014, Journal of the American Academy of Dermatology.

[14]  V. Sondak,et al.  Case–control study of genus‐beta human papillomaviruses in plucked eyebrow hairs and cutaneous squamous cell carcinoma , 2014, International journal of cancer.

[15]  Mona Safizadeh,et al.  Conjunctival squamous cell carcinoma with intraocular invasion after radiotherapy in epidermodysplasia verruciformis. , 2014, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[16]  H. Pfister,et al.  Human papillomavirus and immunosuppression. , 2014, Current problems in dermatology.

[17]  G. Gaud,et al.  Loss of the HPV-Infection Resistance EVER2 Protein Impairs NF-κB Signaling Pathways in Keratinocytes , 2014, PloS one.

[18]  D. Linder,et al.  Acquired Epidermodysplasia Verruciformis: A Comprehensive Review and a Proposal for Treatment , 2013, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[19]  L. Naldi,et al.  Human Papillomavirus Load in Eyebrow Hair Follicles and Risk of Cutaneous Squamous Cell Carcinoma , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[20]  Y. Jacob,et al.  EVER2 protein binds TRADD to promote TNF-α-induced apoptosis , 2013, Cell Death and Disease.

[21]  David A. Williams,et al.  Human RHOH deficiency causes T cell defects and susceptibility to EV-HPV infections. , 2012, The Journal of clinical investigation.

[22]  A. Fischer,et al.  Inherited MST1 Deficiency Underlies Susceptibility to EV-HPV Infections , 2012, PloS one.

[23]  J. Casanova,et al.  EVER2 Deficiency is Associated with Mild T-cell Abnormalities , 2012, Journal of Clinical Immunology.

[24]  L. Dupré,et al.  EVER Proteins, Key Elements of the Natural Anti-Human Papillomavirus Barrier, Are Regulated upon T-Cell Activation , 2012, PloS one.

[25]  O. Sanal,et al.  Additional Diverse Findings Expand the Clinical Presentation of DOCK8 Deficiency , 2012, Journal of Clinical Immunology.

[26]  S. Landolfo,et al.  Lack of EVER2 protein in two epidermodysplasia verruciformis patients with skin cancer presenting previously unreported homozygous genetic deletions in the EVER2 gene. , 2012, The Journal of investigative dermatology.

[27]  P. Itin,et al.  Homozygosity for the c.917A → T (p.N306l) Polymorphism in the EVER2/TMC8 Gene of Two Sisters with Epidermodysplasia Verruciformis Lewandowsky-Lutz Originally Described by Wilhelm Lutz , 2010, Dermatology.

[28]  M. Pawlita,et al.  Seroreactivity of 38 human papillomavirus types in epidermodysplasia verruciformis patients, relatives, and controls. , 2010, The Journal of investigative dermatology.

[29]  Y. Jacob,et al.  The EVER Proteins as a Natural Barrier against Papillomaviruses: a New Insight into the Pathogenesis of Human Papillomavirus Infections , 2009, Microbiology and Molecular Biology Reviews.

[30]  K. Straif,et al.  A review of human carcinogens--Part B: biological agents. , 2009, The Lancet. Oncology.

[31]  T. Mitsuishi,et al.  Epidermodysplasia verruciformis with keratoacanthoma, Bowen's disease and squamous cell carcinoma: isolation of high‐risk types of HPV 5 and unknown type of human papillomavirus , 2008, Journal of the European Academy of Dermatology and Venereology : JEADV.

[32]  Y. Jacob,et al.  Regulation of cellular zinc balance as a potential mechanism of EVER-mediated protection against pathogenesis by cutaneous oncogenic human papillomaviruses , 2007, The Journal of experimental medicine.

[33]  G. Orth Genetics of epidermodysplasia verruciformis: Insights into host defense against papillomaviruses. , 2006, Seminars in immunology.

[34]  D. Ma,et al.  Identification of a novel mutation and a genetic polymorphism of EVER1 gene in two families with epidermodysplasia verruciformis. , 2006, Journal of dermatological science.

[35]  Y. Jacob,et al.  Cottontail Rabbit Papillomavirus E8 Protein Is Essential for Wart Formation and Provides New Insights into Viral Pathogenesis , 2006, Journal of Virology.

[36]  B. Akgül,et al.  HPV‐associated skin disease , 2006, The Journal of pathology.

[37]  U. Dianzani,et al.  CD8+ T-cell lymphocytopenia and lack of EVER mutations in a patient with clinically and virologically typical epidermodysplasia verruciformis. , 2005, Archives of dermatology.

[38]  Xuejun Zhang,et al.  Two frameshift mutations in the RNA-specific adenosine deaminase gene associated with dyschromatosis symmetrica hereditaria. , 2005, Archives of dermatology.

[39]  A. Fischer,et al.  Severe cutaneous papillomavirus disease after haemopoietic stem-cell transplantation in patients with severe combined immune deficiency caused by common γc cytokine receptor subunit or JAK-3 deficiency , 2004, The Lancet.

[40]  T. Kupper,et al.  Immune surveillance in the skin: mechanisms and clinical consequences , 2004, Nature Reviews Immunology.

[41]  A. Griffith,et al.  Characterization of the transmembrane channel-like (TMC) gene family: functional clues from hearing loss and epidermodysplasia verruciformis. , 2003, Genomics.

[42]  B. Hansson,et al.  Prevalence and type spectrum of human papillomaviruses in healthy skin samples collected in three continents. , 2003, The Journal of general virology.

[43]  C. Festa Neto,et al.  Clinical aspects of epidermodysplasia verruciformis , 2003, Journal of the European Academy of Dermatology and Venereology : JEADV.

[44]  S. Heller,et al.  TMC and EVER genes belong to a larger novel family, the TMC gene family encoding transmembrane proteins , 2003, BMC Genomics.

[45]  B. Hansson,et al.  General Acquisition of Human Papillomavirus Infections of Skin Occurs in Early Infancy , 2003, Journal of Clinical Microbiology.

[46]  R. Geha,et al.  Primary immunodeficiency diseases: an update , 2003, Clinical and experimental immunology.

[47]  N. Ramoz,et al.  Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis , 2002, Nature Genetics.

[48]  N. Christensen,et al.  Intracutaneous DNA Vaccination with the E8 Gene of Cottontail Rabbit Papillomavirus Induces Protective Immunity against Virus Challenge in Rabbits , 2002, Journal of Virology.

[49]  N. Ramoz,et al.  Evidence for a nonallelic heterogeneity of epidermodysplasia verruciformis with two susceptibility loci mapped to chromosome regions 2p21-p24 and 17q25. , 2000, The Journal of investigative dermatology.

[50]  Mulder,et al.  Human papillomavirus type 5 is commonly present in immunosuppressed and immunocompetent individuals , 1999, The British journal of dermatology.

[51]  N. Ramoz,et al.  A susceptibility locus for epidermodysplasia verruciformis, an abnormal predisposition to infection with the oncogenic human papillomavirus type 5, maps to chromosome 17qter in a region containing a psoriasis locus. , 1999, The Journal of investigative dermatology.

[52]  S. Jabłońska,et al.  Skin autografts in epidermodysplasia verruciformis: human papillomavirus-associated cutaneous changes need over 20 years for malignant conversion. , 1997, Cancer research.

[53]  G. Orth,et al.  Epidermodysplasia verruciformis. Immunological and nonimmunological surveillance mechanisms: role in tumor progression. , 1997, Clinics in dermatology.

[54]  S. Jabłońska,et al.  Epidermodysplasia verruciformis as a model of human papillomavirus-induced genetic cancers: the role of local immunosurveillance. , 1992, The American journal of the medical sciences.

[55]  D. Lowy,et al.  Antigen presentation and T-cell activation in epidermodysplasia verruciformis. , 1990, The Journal of investigative dermatology.

[56]  G. Orth,et al.  Partial defects of cell-mediated immunity in patients with epidermodysplasia verruciformis. , 1986, Journal of the American Academy of Dermatology.

[57]  M. Yaniv,et al.  Genomic structure of the cottontail rabbit (Shope) papillomavirus. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[58]  E. Chen,et al.  Comparative analysis of the human type 1a and bovine type 1 papillomavirus genomes , 1983, Journal of virology.

[59]  G. Orth,et al.  Characteristics of the lesions and risk of malignant conversion associated with the type of human papillomavirus involved in epidermodysplasia verruciformis. , 1979, Cancer research.

[60]  G. Orth,et al.  Characterization of two types of human papillomaviruses in lesions of epidermodysplasia verruciformis. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[61]  F. Pass,et al.  Depressed immune function in epidermodysplasia verruciformis. , 1977, Archives of dermatology.

[62]  S. Jablonska,et al.  Epidermodysplasia verruciformis as a model in studies on the role of papovaviruses in oncogenesis. , 1972, Cancer research.

[63]  M. Ruiter,et al.  Demonstration by electronmicroscopy of an intranuclear virus in epidermodysplasia verruciformis. , 1966, The Journal of investigative dermatology.

[64]  S. Jabłońska,et al.  Zur Kenntnis der Epidermodysplasia verruciformis Lewandowsky-Lutz , 1957 .

[65]  L. Forman Inherited abnormalities of the skin and its appendages , 1934 .

[66]  F. Lewandowsky,et al.  Ein Fall einer bisher nicht beschriebenen Hauterkrankung (Epidermodysplasia verruciformis) , 1922, Archiv für Dermatologie und Syphilis.

[67]  R. Geha,et al.  Epidermodysplasia verruciformis as a manifestation of ARTEMIS deficiency in a young adult. , 2017, The Journal of allergy and clinical immunology.

[68]  B. Burger,et al.  Epidermodysplasia verruciformis. , 2014, Current problems in dermatology.

[69]  G. Orth Host defenses against human papillomaviruses: lessons from epidermodysplasia verruciformis. , 2008, Current topics in microbiology and immunology.

[70]  J. Casanova,et al.  The human model: a genetic dissection of immunity to infection in natural conditions , 2004, Nature Reviews Immunology.

[71]  Z. H. Hafeez,et al.  Epidermodysplasia verruciformis. , 1996, JPMA. The Journal of the Pakistan Medical Association.

[72]  G. Orth Epidermodysplasia verruciformis: a model for understanding the oncogenicity of human papillomaviruses. , 1986, Ciba Foundation symposium.

[73]  G. Orth,et al.  T cell defect in patients with epidermodysplasia verruciformis due to human papillomavirus type 3 and 5. , 1981, Dermatologica.

[74]  G. Orth,et al.  Twenty-one years of follow-up studies of familial epidermodysplasia verruciformis. , 1979, Dermatologica.

[75]  M. Lutzner Epidermodysplasia verruciformis. An autosomal recessive disease characterized by viral warts and skin cancer. A model for viral oncogenesis. , 1978, Bulletin du cancer.

[76]  Lutzner Ma Epidermodysplasia verruciformis. An autosomal recessive disease characterized by viral warts and skin cancer. A model for viral oncogenesis. , 1978 .

[77]  S. Jabłońska,et al.  Cell-mediated immunity in epidermodysplasia verruciformis. , 1976, Dermatologica.

[78]  K. K. Tan,et al.  Familial epidermodysplasia verruciformis of Lewandowsky and Lutz. , 1972, Archives of dermatology.

[79]  W. Biczysko,et al.  On the viral etiology of epidermodysplasia verruciformis Lewandowsky-Lutz. Electron microscope studies. , 1968, Dermatologica.

[80]  S. Jablonska,et al.  On the viral etiology of epidermodysplasia verruciformis. , 1966, Dermatologica.

[81]  W. Lutz A propos de l’Epidermodysplasie verruciforme , 1946 .